Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company announced that the U.S. Food ...

The Food and Drug Administration (FDA) has approved a tablet formulation of Livmarli ® (maralixibat).

Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille ...

Following the successful Series 2 PRO PLUS launch, Celluma Light Therapy by BioPhotas, Inc., announces the next light therapy solution for 2025 - the full-body Series 2 DELUX.  Sitting at the top of ...

Aside from their great minds, Nicola Tesla, Leonardo Davinci, and Thomas Edison all had something else in common -- they all slept only 2-4 hours in any given 24-hour period.  So these great minds may ...

LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic ...

(Nasdaq: MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

The US Food and Drug Administration’s (FDA) top tobacco regulator, Brian King, has been placed on leave as part of a large wave of cuts across federal health agencies. HealthDay News — The U.S. Food ...

The company’s LIVMARLI drug accounted for $213.3 million of these sales, while its Bile Acid Medicines contributed $123.1 million. Looking forward, Mirum anticipates 2025 global net product sales to ...

Its flagship product, Livmarli (maralixibat), is approved for treating cholestatic pruritus in pediatric ALGS patients, contributing to the company’s revenue. Vivet Therapeutics collaborates ...